Altimeter growth, J&J, FedEx and more

Check out the companies that make headlines before the bell:

Altimeter Growth (AGC) – The Southeast Asian Giant Grab will be released through a SPAC merger with Altimeter Growth, valued at nearly $ 40 billion. Grab says he intends to list the Nasdaq under the symbol “GRAB” after the transaction is completed. Altimeter shares increased by almost 9% in premarket trading.

Johnson & Johnson (JNJ) – Shares of the drug fell 2.8% in the premarket after the Food and Drug Administration said it was calling on states to discontinue J & J’s Covid-19 vaccine after six people in the US developed a rare disorder involving blood clots. The FDA said the recommendation was “out of an abundance of caution.” Moderna shares appeared with over 7% in the early trading of news.

FedEx (FDX) – The shares of the shipping company increased in premarket trading in connection with KeyBanc Capital Markets, which improved FedEx to “overweight”. The Wall Street firm also set a target price of $ 350 per share on FedEx. KeyBanc said FedEx can increase its volume, even with a return to in-person purchases.

JetBlue (JBLU), Spirit Airlines (SAVE) – The shares of the airlines appeared in the premarket trading after Susquehanna Financial Group updated JetBlue and Spirit Airlines to “positive”. “With a recovery in domestic air travel in the US underway, we want to own low-cost carriers,” he told the company’s customer analyst.

Booking Holdings (BKNG) – The tourism company won in premarket trading after Jefferies upgraded Booking to “buy” from “expect” a return of global travel. The former also raised its 12-month price target to $ 2,800 per share from $ 2,300 per share.

3M (MMM) – The shares of the manufacturing giant fell in the premarket after Deutsche Bank added a “catalyst call” sale to 3M. The Wall Street firm said the shares had curiously exceeded in recent weeks, despite Deutsche Bank’s expectations of a loss of future revenue.

NortonLifeLock (NLOK) – The security company fell in premarket trading after Bank of America initiated the shares with a rating of “underperformance” and a target price of $ 19 per share. “Last year’s increase in demand for COVID could relax in the coming quarters and the company could return to negative trends in churn and subscribers, having a negative impact on revenue growth,” the company said.

Honeywell (HON) – Honeywell shares rose in the pre-market after Deutsche Bank gave a catalytic rating “buy” on shares. The company said investors are not enthusiastic about Honeywell, despite the recovery.

Bristol-Myers Squibb (BMY) – The pharmaceutical company’s shares have risen in the premarket that Truist has upgraded Bristol-Myers Squibb to “buy” from the “hold” at a price of $ 74 per share. The Wall Street firm said it likes the Bristol-Myers Squibb drug pipeline.

Did you like this article?
For exclusive stock choices, investment ideas and CNBC’s global broadcast flow
Sign up for CNBC Pro
Start the free trial now

.Source